Skip to main content
3622 search results for:

Lapatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Trastuzumab | Online First

    Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

    Different targeted therapy options exist for treating HER2-positive metastatic breast cancer patients. This study evaluated the efficacy and tolerability of the lapatinib plus capecitabine combination after TDM-1 in HER2-positive metastatic breast …

  2. 01-02-2024 | Lapatinib | OriginalPaper

    Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells

    Endocrine therapy plays a critical role in patients with hormone receptor-positive breast cancer. Endocrine-resistant breast cancer cells exhibit more HER2 signaling proteins (pAKT and pERK) and mesenchymal biomarkers than wild-type cell lines. In …

  3. 01-04-2022 | Tyrosine Kinase Inhibitors | News

    Lapatinib/sorafenib

    Hyperthyroidism and hypothyroidism: 2 case reports
  4. 28-06-2023 | Lapatinib | OriginalPaper

    HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity

    Pathological complete response (pCR) of HER2-positive breast cancer after HER2-directed neoadjuvant chemotherapy is achieved in more than 50% of patients [ 1 ], and is associated with very good overall survival (OS) [ 2 ]. For example, in the …

  5. Open Access 01-12-2021 | Gastric Cancer | OriginalPaper

    A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

    Gastric cancer (GC) is, worldwide, the fourth most common cancer and the second most common cause of deaths of all malignancies [ 1 , 2 ]. The American Cancer Society estimated that there would be about 27,510 new GC cases and 11,140 deaths from GC …

  6. 01-12-2021 | Breast Cancer | Original Research

    An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

    Efforts to expand the utility of PARPi beyond BRCA1/2 have been ongoing, such as inducing a BRCA-like phenotype to create synthetic lethality with PARPi. Our previous preclinical work revealed EGFR inhibition suppressed DNA repair and enhanced …

  7. 01-10-2020 | Metastasis | News

    Lapatinib

    Development of drug resistance in metastatic colorectal cancer: case report
  8. Open Access 01-12-2022 | Breast Cancer | ReviewPaper

    Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

    Globally, breast cancer (BC) is the most common cancer and is the leading cause of tumor-associated mortalities among women. It accounts for about 30% of female cancer incidences and 15% of all cancer deaths [ 1 – 3 ]. Incidence and mortality rates …

  9. 01-12-2020 | Breast Cancer | Original Research

    Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

    Breast cancer is one of the most common invasive cancers and is expected to account for 14% of all cancer deaths in women worldwide [ 1 ]. Activation and overexpression of epidermal growth factor receptor (EGFR, also known as ErbB) family members …

  10. 01-05-2020 | NSCLC | OriginalPaper

    Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

    Approximately 20% of all human cancers carry mutations in the KRAS oncogene, including 90% of pancreatic cancers, 45% of colorectal cancers (CRC), and 35% of non-small cell lung cancers (NSCLC) [ 1 ]. KRAS gain-of-function mutations cause …

  11. Open Access 01-12-2019 | Lapatinib | OriginalPaper

    Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation

    Nasopharyngeal carcinoma (NPC) is a malignancy of head and neck epithelial cells that originates from the nasopharyngeal cavity. NPC is an important health problem in Southern China and Southeast Asia [ 1 ], with about 86,500 NPC new cases recorded …

  12. Open Access 01-11-2019 | Breast Cancer | OriginalPaper

    Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

    Survival is increased in the adjuvant and metastatic settings with human epidermal growth factor 2 (HER2)-targeted treatment in patients with HER2-positive breast cancer [ 1 , 2 ]. A meta-analysis of neoadjuvant trials demonstrated that pathologic …

  13. Open Access 01-12-2019 | Breast Cancer | OriginalPaper

    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

    Human epidermal growth factor receptor (HER2) over-expression is present in about 15–20% of breast cancers [ 1 ]. Until the development of HER2-targeted therapies, this breast cancer subtype was associated with a worse prognosis [ 1 ]. Despite the …

  14. 01-05-2021 | Metastasis | News

    Lapatinib

    Development of resistance in HER2 amplification metastatic breast cancer: case report
  15. 01-12-2021 | Breast Cancer

    HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib

    In HER2+ breast cancer, overexpression and overactivity of the surface-expressed receptor tyrosine kinase human-epidermal growth factor receptor 2 (HER2) is an important driver of cancer growth. Multiple therapeutic inhibitors of HER2 have been …

  16. 01-01-2022 | Lapatinib | Erratum

    Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

    In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here.

  17. Open Access 01-04-2022 | Breast Cancer | OriginalPaper

    Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

    The human epidermal growth factor receptor 2 (HER2/Neu/ErbB2) is amplified and/or overexpressed in approximately 15% of human breast cancers [ 1 ] and plays a direct role in tumor development [ 2 , 3 ]. In patients with breast cancer, HER2 …

  18. 01-03-2020 | Breast Cancer | OriginalPaper

    A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Human epidermal growth factor receptor 2 (HER2) overexpression or gene amplification is present in approximately 15–20% of breast cancers (BC) and identifies patients with poorer prognosis and a more aggressive tumor behavior [ 1 , 2 ]. Targeting …

  19. 01-10-2020 | Metastasis | OriginalPaper

    Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells

    Inflammatory breast cancer (IBC) is an uncommon and highly aggressive form of breast cancer. The disease is characterized by rapid progression with approximately 50% of IBC patients to have human epidermal growth factor receptor 2 (HER2) …

  20. 01-07-2020 | Lapatinib | OriginalPaper

    Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program

    Oral drugs are increasingly used for anticancer treatment [ 1 – 6 ]. A French Unicancer study estimated that [ 7 ] in 2020, the proportion of oral antineoplastic agents would be 50% of all anticancer drugs. Most of the time, these prescriptions are …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.